Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England

Core Insights - Nyxoah has announced the commercial launch of its Genio system in England, with successful implants performed at University College London Hospitals (UCLH) [1][3] - The Genio system is now covered under the NHS Specialised Services Devices Programme (SSDP), facilitating access to innovative therapies [2] Company Overview - Nyxoah is a medical technology company focused on developing neuromodulation treatment alternatives for Obstructive Sleep Apnea (OSA), with its first product being the Genio system [4] - The Genio device is a battery-free hypoglossal neuromodulation device that is inserted through a single incision under the chin and controlled by a wearable [4] Clinical Milestones - The Genio system received its European CE Mark in 2019 following the successful completion of the BLAST OSA study [5] - Positive outcomes from the BETTER SLEEP study led to the expansion of therapeutic indications for Genio to include Complete Concentric Collapse (CCC) patients, which are currently contraindicated in competitors' therapies [5] - The company has also announced positive results from the DREAM IDE pivotal study, which is aimed at obtaining FDA approval for U.S. commercialization [5]